<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229123</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000791-26</org_study_id>
    <nct_id>NCT02229123</nct_id>
  </id_info>
  <brief_title>Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study</brief_title>
  <acronym>LEVNEONAT-1</acronym>
  <official_title>Levetiracetam Efficacy and Safety as First-line Treatment of Neonatal Seizures Occuring in Hypoxic-ischemic Encephalopathy Context</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEVNEONAT is a multicentre French clinical trials with the aim to develop new treatment
      strategies for the treatment of neonatal seizures using Levetiracetam. The purpose of this
      study is to determine the correct dosing, safety and efficacy for intravenous levetiracetam
      as first line treatment in term newborn babies with seizures in hypoxic-ischemic
      encephalopathy context. This new anticonvulsivant drug is a promising treatment for seizures
      in newborns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Article Focus

        -  The principal aim of LEVNEONAT-1 is to determine the levetiracetam optimal dose defined
           as the highest efficient dose under toxicity restrictions for treating neonatal
           seizures.

        -  LEVNEONAT-1 is an open-label, sequential dose-finding study with 4 increasing dose
           levels of levetiracetam.

      Strenghts and limitation of study

        -  For the first time, levetiracetam will be used as the first-line treatment of neonatal
           seizures and not as an add-on therapy.

        -  Statistical model is designed for a rare clinical situation with a sequential adaptive
           method updating in real time the dose allocation for next patient by using all available
           data from previous participants.

        -  The targeted population, i.e. the newborn less than 3 days of life, is particularly
           sensitive and the written consent of both parents is required before the levetiracetam
           administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">October 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>LEVNEONAT-1 is an open and sequential dose-finding study with 1 loading dose of 30, 40, 50 and 60 mg/kg and 8 quarter-loading maintenance doses for a 3-day treatment. The optimal dose will be the one estimated to be associated with a toxicity not exceeding 10% and an efficacy higher than 60%. Efficacy has been defined by a seizure burden reduction of 80% after the loading dose. A 2-patient cohort will be necessary at each dose level to consider an upper dose level assignment with a dynamic consideration of each participant data. The maximal sample size expected is 50 participants with a minimum of 24 patients or less in case of high rate of toxicity.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levetiracetam Efficacy on EEG recording</measure>
    <time_frame>the period just before the LEV loading dose (from 20 min to 3 hours) and the 3 hour time-interval from 1 hour 15 min (T11/4) to 4 hours 15 min (T41/4) after the starting of loading dose infusion (T0)</time_frame>
    <description>Efficacy has been defined as an 80% reduction of seizure burden on EEG recording.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levetiracetam Short-Term Toxicity</measure>
    <time_frame>6 days from the loading dose</time_frame>
    <description>Short-term toxicity focuses on 4 adverse events potentially attributable to LEV occurring in the 6 days following the loading dose: i) Severe apnoea leading to mechanical ventilation during the 4-hour period following the LEV infusion; ii) Anaphylactic shock occurring during the 30 minutes following the LEV infusion; iii) Toxic epidermic necrosis; iv) Stevens-Jonhson Syndrome. Short-term toxicity has been designed to trigger quickly a decreasing dose allocation to the next potential participant through a e-CRF alert.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levetiracetam Long-Term Toxicity</measure>
    <time_frame>30 days from the loading dose</time_frame>
    <description>Long-term toxicity includes all the adverse events observed and declared to the pharmacovigilance unit up to the hospital discharge or the 30th day of life at the latest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Elimination Clearance</measure>
    <time_frame>at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last levetiracetam maintenance dose, respectively.</time_frame>
    <description>The mean values of the elimination clearance and their respective interindividual variability will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Distribution Volume</measure>
    <time_frame>at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last levetiracetam maintenance dose, respectively.</time_frame>
    <description>The mean values of distribution volumes and their respective interindividual variability will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Levetiracetam Maximal Concentration</measure>
    <time_frame>30 min, 4 hours and 7 hours after the end of Levetiracetam loading dose infusion</time_frame>
    <description>Plasmatic Peak Value of Levetiracetam Loading dose will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Loading Dose Area under Curve</measure>
    <time_frame>30 min, 4 hours and 7 hours after the end of Levetiracetam loading dose infusion</time_frame>
    <description>ndividual PK parameters will be estimated and used to calculated the AUC corresponding to the loading dose, after the first maintenance dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Entire Treatment Area Under Curve</measure>
    <time_frame>at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last Levetiracetam maintenance dose, respectively.</time_frame>
    <description>Individual PK parameters will be estimated and used to calculated the cumulative AUC of the entire treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure recurrence from the Efficacy criteria completion to day 6</measure>
    <time_frame>from 4h15 after the loading dose to 6 days</time_frame>
    <description>Clinical or electric seizures recurrence after the efficacy criteria assessment and up to the complete levetiracetam elimination (estimated 5 half-life) will be reported by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Efficacy according to the seizure burden intensity prior to loading dose</measure>
    <time_frame>after the complete recruting period</time_frame>
    <description>A new analysis will be performed retrospectively by adjusting the efficacy criteria to the seizure burden on the pre-treatment EEG. Two subgroups will be considered according to the seizure burden (SB) intensity on the pre-treatment EEG, i.e equal or above to 50% of the EEG recording duration (high SB group) and strictly under 50% of it (low SB group), respectively. LEV efficacy will be considered positive when a SB reduction of 50% will be observed on the post-treatment EEG recording in the high SB group whereas the reduction of 80% will be still valid for the low SB group.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neonatal Seizures</condition>
  <arm_group>
    <arm_group_label>Intravenous levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 loading dose of 30, 40, 50 or 60 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10, 12.5 or 15 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Levetiracetam</intervention_name>
    <description>Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.</description>
    <arm_group_label>Intravenous levetiracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          1. Male or female term baby with gestational age of 36-43 weeks and postnatal age &lt; or=
             72 hours

          2. One or more of the following :

               -  APGAR score &lt; 5 at 5 mins

               -  Umbilical cord or arterial blood sample (within one hour after birth): pH &lt;7.0 or
                  base deficit &gt; or = 16 mmol/L or lactates &gt; or equal to 11 mmol/L

               -  Abnormal neurological examination before 6 hours of life

          3. Suspected clinical or EEG seizures

        Inclusion criteria:

          -  A seizure lasting more than 3 minutes or more than 2 seizures lasting more than 20
             seconds on a 1 hour-period on standard EEG recording 4 hours before the levetiracetam
             loading dose

          -  Availability of 8 electrode EEG recording

          -  Written informed consent of both parents or the authorized guardians

          -  Subscription to social security health insurance are required

        Exclusion Criteria:

          -  Suspected or confirmed brain malformation, inborn error of metabolism, genetic
             syndrome or major congenital malformation

          -  Congenital (in utero) infection (TORCH)

          -  Babies who have received phenobarbital or any other anticonvulsive medication other
             than a bolus of midazolam for intubation

          -  Anuria/renal failure defined as serum creatinine &gt; 150 micromol/L

          -  Seizures secondary to treatable metabolic etiology as hypoglycemia and hypocalcemia

          -  Participation to an interventional research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Weeks</minimum_age>
    <maximum_age>43 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geraldine Favrais, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geraldine FAVRAIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geraldine Favrais, Dr</last_name>
    <phone>0247474749</phone>
    <email>g.favrais@chu-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Estelle Boivin</last_name>
    <phone>0247474620</phone>
    <email>e.boivin@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de réanimation néonatale</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Le Bouedec, Dr</last_name>
      <email>StLeBouedec@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Geraldine Gascoin, Pr</last_name>
      <email>GeGascoin@chu-angers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service de réanimation néonatale</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence Flamein, Dr</last_name>
      <email>Florence.flamein@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurent Storme, Pr</last_name>
      <email>laurent.storme@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Florence Flamein, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Néonatologie</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Pladys, Pr</last_name>
      <email>patrick.pladys@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alain Beuchee, Pr</last_name>
      <email>alain.beuchee@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Pladys, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie néonatale et réanimation</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Chadie, Dr</last_name>
      <email>alexandra.chadie@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stephane Marret, Pr</last_name>
      <email>stephane.marret@chu-rouen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandra Chadie, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néonatologie</name>
      <address>
        <city>Tours</city>
        <zip>37 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldine Favrais, Dr</last_name>
      <phone>0247474749</phone>
      <email>g.favrais@chu-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Estelle Boivin</last_name>
      <phone>0247474620</phone>
      <email>e.boivin@chu-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Geraldine Favrais, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seizures</keyword>
  <keyword>neonates</keyword>
  <keyword>anticonvulsant treatment</keyword>
  <keyword>levetiracetam</keyword>
  <keyword>hypoxic-ischemic encephalopathy</keyword>
  <keyword>electroencephalography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

